drugset / Trial / NCT05429151

Intralesional Injection of Acyclovir Versus Candida Antigen in Treatment of Plantar Warts

NCT05429151

Phase 4 Unknown 40 enrolled Sohag University
RandomizedSequentialSingle-blindTreatment

Summary

This study aims to evaluate the efficacy of intralesional injection of acyclovir versus candida antigen in plantar wart patients will be randomly divided into 2 groups,At least 20 patients will be enrolled in each group. Group 1: will be treated with intralesional injection of acyclovir 250 mg acyclovir vial diluted with 3.5 ml saline to get approximately 70 mg/ml solution. The base of each wart was injected with 0.1 ml of intralesional acyclovir (70 mg/ml) every 2 weeks until the resolution of warts or for a maximum of 5 sessions Group 2: will be treated by intralesional Candida antigen injection (candida antigen ) at a dose of 0.2 mL. injected into the largest wart every 2 weeks until complete clearance of warts or for a maximum of 5 treatment sessions. 3.Patient evaluation: Assessment of treatment efficacy and side effects will be carried out by clinical examination and comparative photographic evaluation and dermoscopy

Timeline

Start
2022-06-13
Primary completion
2022-11-30
Completion
2023-05-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Acyclovir Small molecule 70 mg/ml Other
Comparator Candida antigen Vaccine 0.2 ml Other

Indications

No indication recorded.